<DOC>
	<DOCNO>NCT00004700</DOCNO>
	<brief_summary>OBJECTIVES : Evaluate safety efficacy long term recombinant human insulin-like growth factor I child hyperinsulinism .</brief_summary>
	<brief_title>Phase II Long Term , Randomized Study Recombinant Human Insulin-like Growth Factor I Children With Hyperinsulinism</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This randomize , double blind , placebo control , cross-over study . Patients randomize receive recombinant human insulin-like growth factor I ( IGF-I ) placebo subcutaneously twice daily 4 week . After 2 week washout period , patient cross regimen additional 4 week . Completion date provide represent completion date grant per OOPD record</detailed_description>
	<mesh_term>Hyperinsulinism</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Complement Factor I</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Diagnosis hyperinsulinism ( i.e. , evidence fast hypoglycemia inadequate suppression insulin , normal pituitary adrenal function , increased insulin action ) Suboptimal control blood sugar ( i.e. , inability fast least 10 hour blood sugar 60 mg/dL great ) Prior/Concurrent Therapy See Disease Characteristics Patient Characteristics Performance status : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : No major medical condition No know adverse reaction recombinant human insulinlike growth factor I</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 1999</verification_date>
	<keyword>endocrine disorder</keyword>
	<keyword>hyperinsulinism</keyword>
	<keyword>rare disease</keyword>
</DOC>